Lilly launches Foundayo, its oral GLP-1

Eli Lilly's oral GLP-1 medicine orforglipron reached US patients on April 9, 2026, under the brand name Foundayo, priced at $149 a month for people paying cash. Early prescription volumes trailed Novo Nordisk's Wegovy pill, a sign that Lilly's obesity business still leans heavily on its injectable tirzepatide products, Mounjaro and Zepbound.

Foundayo is the brand name for orforglipron, a small-molecule GLP-1 taken by mouth. That matters because it is chemically different from semaglutide, the molecule in Ozempic, Wegovy and the oral tablet Rybelsus. Semaglutide is a peptide, which is harder to formulate as a pill. Small molecules like orforglipron are generally easier and cheaper to manufacture at scale, which is part of why analysts have watched this launch closely.

What we can and cannot confirm

The two news reports attached to this development could not be retrieved, so several specifics are not verifiable here. A Reuters report published April 17, 2026 was titled to reference roughly 1,390 US prescriptions for Lilly's obesity pill in its launch week, but the article text was unavailable ^[1]. A Fierce Pharma piece framed Foundayo's launch as a disappointment while Lilly's injectables continued to grow, though its text was also unavailable ^[2].

Because of that, this story does not carry confirmed details on Foundayo's approved uses, label wording, dosing schedule, side-effect profile, or how the $149 self-pay price is structured, such as whether it applies to all doses, requires enrollment in a direct-to-consumer program, or changes after an introductory period. Insurance coverage terms are also not yet known from these sources. Head-to-head comparisons of weight loss between orforglipron and semaglutide are not established by anything cited here.

The comparison point in the summary is Novo Nordisk's Wegovy pill, an oral form of semaglutide. Exact prescription numbers for that product over the same period are not available in these sources, so the size of the gap cannot be stated precisely. What the reporting indicates is directional: Foundayo's opening weeks came in below the oral semaglutide benchmark, and below what some observers expected.

Why it matters for patients

A slow start does not tell a patient whether a drug works for them. It does, however, shape the practical environment around a prescription.

Supply is one piece. Launches that begin modestly are less likely to strain manufacturing early on, though that can change quickly if demand builds. Pricing is another. A $149 monthly self-pay figure sits well below the list prices that have defined the injectable GLP-1 market, and cash-pay channels have become a common way people access these medicines when insurance says no. Whether that price holds, and what it covers, is something patients would need to confirm directly.

Coverage decisions by insurers and pharmacy benefit managers often follow real-world uptake and negotiated rebates. Early volumes can influence where a drug lands on a formulary, and how much prior authorization paperwork stands in the way.

Finally, a pill is not automatically a better fit than an injection. The trade-offs involve administration requirements, tolerability, cost and coverage, and none of those are uniform across patients. Those are conversations for a prescriber.

What happens next

April 9, 2026: Foundayo becomes available to US patients [summary]. April 17, 2026: Reuters reports on launch-week prescription volume ^[1]. Lilly's next quarterly earnings report should give the first company-level read on how Foundayo is selling relative to Mounjaro and Zepbound; a date for that disclosure is not yet known from these sources.